Riphenidate en es it fr

Riphenidate Brand names, Riphenidate Analogs

Riphenidate Brand Names Mixture

  • No information avaliable

Riphenidate Chemical_Formula


Riphenidate RX_link

Riphenidate fda sheet

Riphenidate FDA

Riphenidate msds (material safety sheet)

Riphenidate MSDS

Riphenidate Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Riphenidate Molecular Weight

233.306 g/mol

Riphenidate Melting Point


Riphenidate H2O Solubility


Riphenidate State


Riphenidate LogP


Riphenidate Dosage Forms

Tablets; Tablets (sustained release)

Riphenidate Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Riphenidate Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Riphenidate Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Riphenidate side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Riphenidate Patient Information

Riphenidate Organisms Affected

Humans and other mammals